Diabetes and hypertension and atherosclerotic cardiovascular disease: Related or separate entities often found together

Hypertension

Volumn 57, Issue 5, 2011, Pages 887-888

  Torp Pedersen, Christian ^a   Jeppesen, Jørgen ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; STROKE;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION;

EID: 79955463112     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.168583     Document Type: Note

References (9)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The N Engl J Med. 1998;339:229-234. (Pubitemid 28350165)
2. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardio-vascular risk: a population study of 3.3 million people. Circulation. 2008; 117:1945-1954. (Pubitemid 351543470)
3. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007; 115:1544-1550. (Pubitemid 46648639)
4. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) ran-domised trial-HOT Study Group. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
5. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57:891-897.
6. Sehestedt T, Hansen TW, Richart T, Boggia J, Kikuya M, Thijs L, Stolarz-Skrzypek K, Edoardo C, Tikhonoff V, Malyutina S, Nikitin Y, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Lind L, Torp-Pedersen C, Jeppsen J, Ibsen H, Imai Y, Want J, Sandoya E, Kawecka-Jaszcz K, Staessen JA. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens Res. Epub ahead of print February 10, 2011.
7. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 362:1575-1585.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
9. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)